Clinical and Translational User Group Meetings +

Going beyond: Molecular evidence for off-label therapy use

24 views
June 02, 2021
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital Insights explains
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies

Related videos

Clinical and Translational User Group Meetings +

Secondary analysis: From NGS data to variant identification and visualizationin the cloud

16 views June 07, 2021

Ajay Athavale, Ph.D., Senior manager, Clinical services, QIAGEN Digital...

Clinical and Translational User Group Meetings +

Confidence and trust: Deliver valuable clinical insights with high-quality knowledge

19 views June 02, 2021

Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...

Clinical and Translational User Group Meetings +

Variant reporting: Generate oncologist-ready clinical reports from comprehensive cancer panels in...

20 views June 02, 2021

Ruth Burton, Ph.D., Clinical Application Specialist, QIAGEN Digital Insights...

Clinical and Translational User Group Meetings +

Secondary Analysis: From NGS data to Variant identification and visualization

33 views June 02, 2021

Cristian Cosentino, Ph.D., Senior Field Bioinformatics Application...